sodium oxybate
Generic: SODIUM OXYBATE·Brand: LUMRYZ, SODIUM OXYBATE, XYREM
sodium oxybate: developed by 2 companies · 1 clinical trial tracked.
sodium oxybate evidence translation
What we can confirm
1 tracked trial
What it means
More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about sodium oxybate, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Cataplexy or excessive daytime sleepiness (EDS) in adults and pediatric patients seven years of age and older with narcolepsy; being evaluated for idiopathic hypersomnia (REVITALYZ phase 3 randomized withdrawal study)Narcolepsy
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| Alkermes plc. (ALKS) Cataplexy or excessive daytime sleepiness (EDS) in adults an… | Approved |
| AVADEL PHARMACEUTICALS PLC (AVDL) | Phase 3 |
Clinical Trials (1)
A Prospective, Multicenter, Observational Study of LUMRYZ Used in Clinical Practice for the Treatment of Narcolepsy
Primary endpoint: Epworth Sleepiness Scale
Observational71 enrolledStarted 2024-07Completion 2025-1012 sites · United StatesAvadel
Frequently asked questions
Who is developing sodium oxybate?
sodium oxybate is being developed by Alkermes plc., AVADEL PHARMACEUTICALS PLC.
How many clinical trials involve sodium oxybate?
BioSniper tracks 1 clinical trial involving sodium oxybate.